Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is a leading gene therapy company with a robust pipeline that includes programs for various devastating diseases such as hemophilia, Huntington's disease, and cardiovascular diseases. With promising data from its AMT-260 trial in refractory epilepsy patients and positive regulatory updates for its AMT-130 program, the company is making significant progress towards its goal of commercializing gene therapies. While there are risks involved, including clinical development, commercialization, and pricing risks, uniQure's strong financials, and ongoing research programs make it a promising stock to invest in.

Bears say

uniQure is currently facing timing risks for its gene therapy program, AMT-130, due to potential delays in the regulatory process. There is also the risk of competition from other gene therapy companies with similar treatments in development. Additionally, the company's financials could be negatively impacted by any potential clinical trial failures or setbacks, and its valuation may be too high given the uncertainties surrounding its pipeline.

uniQure (QURE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 12 analysts, uniQure (QURE) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.